A Spanish National PBPC Donor Registry has recently been established for short-and long-term safety data collection in normal donors receiving rhG-CSF. To date, 466 donors have been included in the Registry. Median (range) dose and duration of rhG-CSF administration was 10 g/kg/day (4-20) and 5 days (4-8), respectively. Donors underwent a median of two aphereses (range, 1-5). Adverse effects consisted mainly of bone pain (90.2%), headache (16.9%) and fever (6.1%), but no donor discontinued rhG-CSF prematurely due to toxicity. Side-effects were more frequent in donors receiving Ͼ10 g/kg/day than in those with lower doses (82.8% vs 61.8%; P = 0.004). A significant decrease between baseline and post-apheresis platelet counts was the most important analytical finding (229 ؋ 10 /kg. No definitive information about potential long-term side effects is yet available. However, we hope this National Registry will serve as a useful basis for better monitoring of the efficiency and side-effects of cytokine administration in healthy people. Keywords: granulocyte colony-stimulating factor; normal donors; stem cell mobilization; side-effects Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is being widely used to treat neutropenia secondary to chemotherapy and to collect peripheral blood progenitor cells (PBPC) for use in autologous transplantation. [1] [2] [3] More recently, rhG-CSF has been given to healthy people for granulocyte collection, 4,5 and to mobilize and collect PBPC for allogeneic transplants. [6] [7] [8] [9] [10] In the allogeneic setting, the routine use of mobilized PBPC must be based not only on clinical results, but also on the safety of donors. remain important issues. Regarding this, the optimal dose and schedule of rhG-CSF for mobilization of PBPC have not been definitively established, and specific information about short-and long-term biological and clinical effects of rhG-CSF in normal donors is still limited. Thus, a prolonged follow-up of donors is clearly needed in order to rule out the development of toxicity and to ensure that administration of this cytokine to healthy individuals is completely devoid of long-term side-effects. This task will be more easily approached by the development of PBPC national or international donor registries that allow the inclusion of higher number of donors. 11, 12 In Spain, a National PBPC Donor Registry has recently been developed to address potential adverse effects of the administration of rhG-CSF to normal donors for PBPC mobilization and collection. The objectives of this registry include a standardized data collection for the different centers administering rhG-CSF to normal donors for PBPC mobilization and collection, and a better knowledge of the incidence and nature of the side-effects observed in healthy people given rhG-CSF. Finally, donors will undergo a long-term follow-up including periodic contacts to monitor the possible appearance of long-term side-effects in this population.
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We present the preliminary clinical and laboratory results of rhG-CSF administration for PBPC mobilization and collection in 466 normal donors currently included in the Spanish National Donor Registry. In the present report we will focus on PBPC mobilization and collection as well as initially assess the short-term side-effects of the procedure.
Materials and methods

Donor characteristics
Between September 1993 and October 1998, 466 healthy individuals from 23 Spanish centers received rhG-CSF as the mobilization agent for PBPC collection. These donors underwent 476 procedures of mobilization and form the basis of the present analysis. Data available for donors up to October 1997 were retrospectively collected. Since then, information was prospectively monitored by means of a standardized data sheet. Detailed written informed consent was obtained from each donor before the start of the procedure. In the case of minors, the informed consent was provided by their guardian.
General donor information contained in the data sheet includes age, sex, and grade of HLA matching. Serology for hepatitis B and hepatitis C virus, cytomegalovirus and Epstein-Barr virus was routinely collected. Likewise, at the time of initial assessment, a complete blood count (CBC) and biochemistry survey were obtained. Blood chemistry included glucose, urea nitrogen, creatinine, uric acid, total bilirubin, alkaline phosphatase (AP), lactate dehydrogenase (LDH), alanine aminotransferase, aspartate aminotransferase, and gamma glutamyl transferase (GGT). These hematological and chemistry profiles were repeated immediately after the last apheresis. Finally, a physical examination, CBC, and biochemistry profile was performed within the next 4 weeks after PBPC collection. Donors were questioned about side-effects observed during rhG-CSF administration and analgesic requirements. Adverse events were recorded at every institution and graded according to duration of symptoms, and whether, or not, the donors required medication for pain or symptom relief.
PBPC mobilization and collection
Data on PBPC mobilization included type of rhG-CSF (filgrastim or lenograstim) administered and dose and number of days of rhG-CSF administration. Information about the type of venous access used for PBPC collection was generally obtained, as well as data about the number of stem cell collections performed. The number of CD34 + cells collected after each apheresis was also requested.
Statistical analysis
Statistical analysis was performed by using BMDP statistical software. 13 Data were analyzed using the non parametric Mann-Whitney test for continuous variables, and chisquared for categorical variables.
Results
Two hundred and seventy-three donors (58.5%) were male and 193 (41.5%) female, with a median age of 35 years (range, 1-71). Twenty-three donors (4.9%) were younger than 14 years, and 18 (3.8%) were older than 60 years. According to the type of donor, 416 were HLA-identical sibling, 29 were non HLA-identical related donors, there were 11 monozygotic twins, and eight were HLA-phenotypically identical related donors. Finally, there were two unrelated donors. Main donor characteristics are shown in Table 1 .
rhG-CSF administration
rhG-CSF was the only cytokine administered, 387 (81.3%) donors received filgrastim (Amgen, Thousands Oaks, CA, USA), and 64 (13.4%) lenograstim (Rhône-Poulenc, Paris, France). Finally, in 25 of them (5.3%) such information was not available. Median dose of rhG-CSF administered was 10 g/kg/day (range, 4-20) , with 387 (81.3%) donors receiving 10 g/kg/day. Seventy-two donors received Ͼ10 g/kg/day (median 12 g/kg; range, 10.8-20) , and only 17 donors (3.6%) received Ͻ10 g/kg/day (median 5 g/kg; range, 4-9). Median duration of rhG-CSF administration was 5 days (range, 4-8).
PBPC collection
Median number of aphereses performed was two (range, 1-5), with 175 donors (37.5%) undergoing only one PBPC collection. In 418 out of the 476 mobilization procedures aphereses were done through bilateral peripheral venous access, and in the remaining 36 procedures (7.5%) a placement of a central venous line was required for adequate PBPC harvest. Finally, nine donors underwent more than one mobilization procedure (two procedures in eight of them, and three procedures in the remaining one) with a median interval between PBPC mobilizations of 105 days (range, 14-388).
Donor side-effects
Information about adverse events was available in 293 out of the 476 procedures (61.5%), with 195 (66.5%) presenting some rhG-CSF-related toxicity. Bone pain was the finding most frequently observed (90.2%) followed by headache (16.9%) and fever (6.1%). Other effects attributed to rhG-CSF were fatigue (5.6%) and nausea (2.6%). Fewer individuals presented insomnia or itching. One hundred and thirty-nine donors (71.2%) required analgesics for bone pain and/or headache relief, but no donor discontinued rhG-CSF prematurely due to toxicity. Side-effects were more frequently reported in donors receiving Ͼ10 g/kg/day of rhG-CSF than in those with lower doses (82.8% vs 61.8%; P = 0.004), although severity was the same in both groups. Finally, toxicity resolved within a week in every case.
Effects on peripheral blood counts
The effects of rhG-CSF administration on hematologic and chemistry values are shown in Table 2 . As expected, rhG-CSF caused an increase in the absolute leukocyte count from a mean baseline value of 6.6 × 10 9 /l (range, 3.3-17) to 47.1 × 10 9 /l (range, 17.6-142) (P Ͻ 0.0001). Likewise, the platelet count suffered a significant decrease between baseline and post-apheresis values. Mean platelet count immediately before collection and after last apheresis was 229 × 10 9 /l (range, 124-636) and 140 × 10 9 /l (range, 23-440), respectively (P Ͻ 0.0001). The platelet counts fell below 100 × 10 9 /l in 22.6% of the donors, and below 50 × 10 9 /l in 3.9%, with a minimum of 23 × 10 9 /l. However, those counts returned to Ͼ100 × 10 9 /l within the 2 following weeks in every donor. In the donors undergoing two or more aphereses, there was a progressive reduction in platelet count with each apheresis procedure. The median (range) platelet counts after first, second, third, fourth and fifth apheresis were 167 (60-440), 118 (23-340), 88 (23-300), 63 (25-93) and 33 (32-34) × 10 9 /l. This decrease in platelets was not associated with bleeding symptoms. Finally, hemoglobin concentration exhibited a slight but significant decrease after last apheresis as compared to baseline values, although it was asymptomatic (Table 2) .
Effects on chemistry parameters
In serum chemistry, rhG-CSF caused a two-fold increase in AP and LDH concentrations ( Table 2) . Uric acid levels increased from 4.8 mg/dl to 5.5 mg/dl (P = 0.0002). The serum levels of GGT and transaminases remained within the normal range, and no significant variations were observed in the other serum chemistries monitored.
Other side-effects related to PBPC collection
One donor developed pneumothorax that required hospitalization due to central venous line placement. No other side-effects related to central line placement were reported.
CD34
+ cells collected Overall, the mean CD34 + cell dose collected was 6.9 × 10 6 /kg (range, 1.3-36). According to the median dose Table 2 Effects of rhG-CSF on hematological and chemistry parameters of rhG-CSF administered donors were divided into three different groups, Ͻ10, 10 and Ͼ10 g/kg/day. As is shown in Figure 1 , in every group for a given dose of rhG-CSF, the CD34 + cell yield decreased from the first to subsequent apheresis.
The quantity of CD34 + cells collected was related to the dose of rhG-CSF administered. According to the donor's weight, when rhG-CSF was given for 5 days, more CD34 + cells were collected from people given Ͼ10 g/kg/day (mean Ϯ s.d., 7.3 Ϯ 4.1 × 10 6 /kg) than for those given Ͻ10 g/kg/day (mean Ϯ s.d., 5.1 Ϯ 3.9 × 10 6 /kg), or 10 g/kg/day (mean Ϯ s.d., 6.7 Ϯ 3.6 × 10 6 /kg), although differences were not statistically significant (Figure 2 ). When only donors receiving 10 g/kg/day were considered, the PBPC collected from people treated for 5 days contained more CD34
+ cells (mean Ϯ s.d., 7.8 Ϯ 6.1 × 10 6 /kg) than those collected after 4 days of rhG-CSF (mean Ϯ s.d., /kg) (P = 0.005). Finally, we did not observe any correlation between age and CD34 + cell yield.
Blood counts after rhG-CSF administration
Those donors with a CBC count performed in the 3 weeks following PBPC collection showed values within the normal range, although their leukocyte and hemoglobin values remained below their baseline levels (Table 2) . Finally, serum chemistry parameters returned to normal values within 3 weeks after the last apheresis.
Discussion
Collection of PBPC in healthy subjects implies the administration of a recombinant hemopoietic growth factor, mainly rhG-CSF, to mobilize PBPC into the circulation. However, the administration of rhG-CSF is not completely devoid of side-effects and donor safety is a critical issue with regard to the use of mobilized PBPC for allogeneic transplants. In order to have a better knowledge of the effects of rhG-CSF administration to normal donors, we have evaluated the mobilization efficacy and toxicity in 466 healthy individuals undergoing 476 mobilization procedures included in the Spanish National Donor Registry. As in other series, [14] [15] [16] [17] [18] [19] [20] most of the donors presented some immediate sideeffects, bone pain and headache being the toxicities most frequently observed, although they were easily managed with mild analgesics and resolved promptly after rhG-CSF discontinuation.
Severe side-effects, occasionally reported, [21] [22] [23] were not observed by us, and no donor required hospitalization or premature suspension of rhG-CSF due to toxicity, a toxicity profile that seems to compare favorably with that of bone marrow harvesting. 24, 25 As expected, serum chemistry abnormalities were uniformly observed in every donor, with the most important changes detected in serum AP and LDH levels. It is generally accepted that these findings are not due to liver toxicity, but related to the rhG-CSF-induced neutrophilia. 16, 17, 26, 27 As in other series, 14, [16] [17] [18] [28] [29] [30] PBPC collection resulted in a significant decrease in the platelet count in all donors, although no bleeding episodes occurred. Thrombocytopenia was directly related to the number of apheresis procedures, and it was especially important in donors undergoing three or more apheresis procedures. A valid approach to try to reduce the degree of thrombocytopenia could be the reinfusion of the autologous platelet-rich plasma at the end of the procedure. 31 Some authors have reported that a short course of rhG-CSF caused a mild but significant decrease in platelet counts, suggesting that thrombocytopenia during PBPC collection may, too, be due to an additional rhG-CSF-related mechanism. 16, 18, 29, 30 From our point of view, platelet counts must be routinely monitored during PBPC collections especially in donors undergoing more than two PBPC collections. Finally, lymphocytosis 16 and lymphopenia 28 have been described after rhG-CSF administration in normal donors. Unfortunately, the lymphocyte count is not routinely obtained in our Registry, thus additional studies will be needed to know definitively the evolution of lymphocytes during rhG-CSF administration.
In our Registry, 7.5% of the donors needed a central venous line for stem cell collection, with only one donor developing a significant complication that required hospitalization (pneumothorax), a lower number than that reported by single institutions 6, 9, 20, 30 or other registries. 32 Although not rhG-CSF-related, the placement of a central venous access must be included in the whole procedure of PBPC mobilization and collection. Although the insertion of a central venous catheter may be safer than a marrow harvest under general anesthesia, it is not without significant risks and may be difficult to justify in a volunteer donor. 15, 16 Regarding this, we believe that although the placement of a central venous line is not without risks and should be avoided whenever possible, it is still a safer procedure than a bone marrow harvest under general anesthesia 24, 25 and does not necessarily preclude the collection of PBPC.
In our series, the median dose of rhG-CSF administered was 10 g/kg/day for 5 days. Although the optimal rhG-CSF dose and schedule for mobilization in normal donors has not been definitively established, this dose has been shown as a highly effective regimen for autologous PBPC mobilization, 14, 15, 17 and a similar schedule has been recently recommended by the EBMT group. 11 We did not find a clear correlation between the CD34 + cell yield and the dose and duration of rhG-CSF administration, although there was a trend for better collection with higher doses of rhG-CSF (у10 g/kg/day). This finding could be due to the fact the median dose of rhG-CSF administered in the higher dose group was only 12 g/kg/day, instead of the 16 30 or 24 g/kg/day 33 administered by other groups. Likewise, administration of rhG-CSF twice a day could have played a role in the different yield of CD34 + cells reported by other authors, 30 ,33 a fact not analyzed by us. However, we found a significantly higher incidence of side-effects in donors receiving the higher rhG-CSF dose. Taken together, these findings confirm that 10 g/kg/day of rhG-CSF for 4-5 days appears to be a good regimen for mobilization and collection of PBPC cells in the majority of normal donors. Nevertheless, prospective randomized trials comparing different doses and schedules of rhG-CSF administration need to be done to establish definitively the optimum regimen for PBPC mobilization in normal donors.
Our data, as well as that reported by others, 15, 34, 35 clearly indicate that some volunteers are intrinsically poor responders to rhG-CSF, although due to low numbers, no specific characteristics could be identified as a predictive factor for response to rhG-CSF administration in these 'poor' mobilizers. In these cases, alternative approaches to PBPC mobilization need to be investigated. 36, 37 Currently, there are very few data to evaluate the potential risk of long-term effects related to rhG-CSF administration, 38 and this issue remains open. In fact, some authors have suggested that before the use of allogeneic PBPC can be routinely recommended, more information on donor safety must be obtained, 39 and a prolonged follow-up of donors to monitor the possible appearance of late effects has been widely recommended. This monitoring should ideally be based on large multicenter or national donor registries. 11, 12, 18, 40 However, to date, no general guidelines about the follow-up of donors have been published. The Spanish National Donor Registry that includes the most important Spanish transplant centers is the first one to develop this objective. Long-term follow-up of donors, including periodic contacts (one per year for at least 5 years) has been planned in order to detect possible long-term complications of rhG-CSF administration. Although there are still insufficient data to evaluate the potential possible long-term sequelae of the procedure properly, we hope it will serve as a useful basis for better monitoring of the efficiency and side-effects of cytokine administration for PBPC mobilization and collection approaches in healthy people.
